zemocimig

Zemocimig (NXT007) is an investigational, next-generation bispecific monoclonal antibody designed for the treatment of hemophilia A. Developed by Chugai Pharmaceutical (a member of the Roche Group) and Hoffmann-La Roche, it mimics the cofactor function of activated factor VIII (FVIII) by binding to factor IXa and factor X. This action restores the intrinsic tenase activity necessary for blood coagulation in patients who either lack or have inhibitors to FVIII. Administered via subcutaneous injection, zemocimig is engineered to provide potent and potentially more convenient prophylaxis compared to existing therapies. It is currently being evaluated in Phase III clinical trials, including head-to-head studies against emicizumab (Hemlibra) and standard-of-care factor VIII prophylaxis.

Other names

Zemocimig